Results From a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Repository Corticotropin Injection for the Treatment of Pulmonary Sarcoidosis
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource, 1 online resource.
- Sprache
-
Englisch
- Erschienen in
-
Results From a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Repository Corticotropin Injection for the Treatment of Pulmonary Sarcoidosis ; volume:9 ; number:2 ; day:19 ; month:4 ; year:2023 ; pages:237-253 ; date:6.2023
Pulmonary therapy ; 9, Heft 2 (19.4.2023), 237-253, 6.2023
- Urheber
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s41030-023-00222-2
- URN
-
urn:nbn:de:101:1-2023091012071198001724
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:57 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Mirsaeidi, Mehdi
- Baughman, Robert P.
- Sahoo, Debasis
- Tarau, Eva
- SpringerLink (Online service)
Ähnliche Objekte (12)
Repository corticotropin for Chronic Pulmonary Sarcoidosis
Repository Corticotropin Injection for the Treatment of Pulmonary Sarcoidosis: A Narrative Review
Repository Corticotropin Injection for Persistently Active Systemic Lupus Erythematosus: Results from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
Correction to: Repository Corticotropin Injection for Persistently Active Systemic Lupus Erythematosus: Results from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
Patient-Reported Outcomes from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Repository Corticotropin Injection (Acthar® Gel) for Persistently Active Systemic Lupus Erythematosus
Post Hoc Biomarker Analyses from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Repository Corticotropin Injection (Acthar® Gel) for Persistently Active Systemic Lupus Erythematosus
Repository Corticotropin in Treating de novo C3 Glomerulonephritis after Transplantation
Efficacy and tolerability of subcutaneous repository corticotropin injection in refractory ocular inflammatory diseases
A Narrative Review of Repository Corticotropin Injection for the Treatment of Systemic Lupus Erythematosus
Repository Corticotropin Injection for Active Rheumatoid Arthritis Despite Aggressive Treatment: A Randomized Controlled Withdrawal Trial
Sarcoidosis
Repository corticotropin injection versus corticosteroids for protection against renal damage in a focal segmental glomerulosclerosis rodent model
Repository corticotropin for Chronic Pulmonary Sarcoidosis
Repository Corticotropin Injection for the Treatment of Pulmonary Sarcoidosis: A Narrative Review
Repository Corticotropin Injection for Persistently Active Systemic Lupus Erythematosus: Results from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
Correction to: Repository Corticotropin Injection for Persistently Active Systemic Lupus Erythematosus: Results from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
Patient-Reported Outcomes from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Repository Corticotropin Injection (Acthar® Gel) for Persistently Active Systemic Lupus Erythematosus
Post Hoc Biomarker Analyses from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Repository Corticotropin Injection (Acthar® Gel) for Persistently Active Systemic Lupus Erythematosus
Repository Corticotropin in Treating de novo C3 Glomerulonephritis after Transplantation
Efficacy and tolerability of subcutaneous repository corticotropin injection in refractory ocular inflammatory diseases
A Narrative Review of Repository Corticotropin Injection for the Treatment of Systemic Lupus Erythematosus
Repository Corticotropin Injection for Active Rheumatoid Arthritis Despite Aggressive Treatment: A Randomized Controlled Withdrawal Trial
Sarcoidosis
Repository corticotropin injection versus corticosteroids for protection against renal damage in a focal segmental glomerulosclerosis rodent model
Repository corticotropin for Chronic Pulmonary Sarcoidosis
Repository Corticotropin Injection for the Treatment of Pulmonary Sarcoidosis: A Narrative Review
Repository Corticotropin Injection for Persistently Active Systemic Lupus Erythematosus: Results from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
Correction to: Repository Corticotropin Injection for Persistently Active Systemic Lupus Erythematosus: Results from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
Patient-Reported Outcomes from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Repository Corticotropin Injection (Acthar® Gel) for Persistently Active Systemic Lupus Erythematosus
Post Hoc Biomarker Analyses from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Repository Corticotropin Injection (Acthar® Gel) for Persistently Active Systemic Lupus Erythematosus
Repository Corticotropin in Treating de novo C3 Glomerulonephritis after Transplantation
Efficacy and tolerability of subcutaneous repository corticotropin injection in refractory ocular inflammatory diseases
A Narrative Review of Repository Corticotropin Injection for the Treatment of Systemic Lupus Erythematosus
Repository Corticotropin Injection for Active Rheumatoid Arthritis Despite Aggressive Treatment: A Randomized Controlled Withdrawal Trial
Sarcoidosis